Three large Phase III clinical studies of PD1/PD-L1 in combination with TKI for first-line treatment of RCC, Immotion-151, JAVELIN Renal 101, and KEYNOTE-426, have also achieved breakthrough results, which also provide clinicians with more treatment options [29, 31, 32]. Here, CD274 is linked to renal cell carcinoma.